OKYO Pharma Announced That Screening And Recruitment Of Patients Has Started For A Phase 2 Trial Of OK-101 Neuropathic Corneal Pain

The Phase 2 study is designed as a double-masked, randomized, 12-week placebo-controlled trial in NCP patients. A total of 48 patients are planned to enroll for the study, with NCP disease confirmed via confocal microscopy. The primary endpoint of this study is to measure pain relief using Visual Analog Scale (VAS) scale.